Luis Leal-Vega, María Begoña Coco-Martín, Adrián Martín-Gutiérrez, José Antonio Blázquez-Cabrera, Francisca Arranz-García, Amalia Navarro, María Jesús Moro, José Filgueira, Manuel Sosa-Henríquez, María Ángeles Vázquez, María José Montoya, Manuel Díaz-Curiel, José Manuel Olmos, José Luis Pérez-Castrillón, OSTEOMED Group
{"title":"合并症和多病对骨质疏松症患者骨密度的影响","authors":"Luis Leal-Vega, María Begoña Coco-Martín, Adrián Martín-Gutiérrez, José Antonio Blázquez-Cabrera, Francisca Arranz-García, Amalia Navarro, María Jesús Moro, José Filgueira, Manuel Sosa-Henríquez, María Ángeles Vázquez, María José Montoya, Manuel Díaz-Curiel, José Manuel Olmos, José Luis Pérez-Castrillón, OSTEOMED Group","doi":"10.1007/s11657-025-01604-6","DOIUrl":null,"url":null,"abstract":"<div><h3>\n <i>Summary</i>\n </h3><p>This retrospective cohort study analysed a total of 344 patients from the OSTEOMED registry with matched baseline and follow-up DXA data, finding that comorbidities such as nephrolithiasis, hypertension or coronary heart disease may influence the response to prescribed anti-osteoporotic treatment.</p><h3>Purpose</h3><p>To determine: 1) comorbidities associated with reduced bone mineral density (BMD), T-score and Z-score at the lumbar spine (L1 to L4 vertebrae), femoral neck and total hip; and 2) the role of multimorbidity (≥ 2 comorbidities) in reduced BMD, T-score and Z-score at the lumbar spine, femoral neck and total hip.</p><h3>Methods</h3><p>Retrospective cohort study analyzing patients [319 females (92.73%), 25 males (7.27%), age 62.13 ± 10.46 years] from the OSTEOMED registry with matched baseline and follow-up dual-energy X-ray absorptiometry (DXA) data. Patients' sex, age, body mass index (BMI), comorbidities and treatments were collected from their medical records after they had given written informed consent.</p><h3>Results</h3><p>Considering a least significant change (LSC) of 4.2%, neither comorbidity nor multimorbidity was statistically significantly associated with a reduction in BMD in any of the bone regions studied. However, binary logistic regression analyses adjusted for sex, age, BMI and treatments showed that nephrolithiasis (<i>p</i> = 0.044) and coronary heart disease (<i>p</i> = 0.026) were statistically significantly associated with a reduction in total hip T-score and that hypertension (<i>p</i> = 0.049) and coronary heart disease (<i>p</i> = 0.01) were statistically significantly associated with a reduction in total hip Z-score.</p><h3>Conclusion</h3><p>Despite comorbidity and multimorbidity, patients with osteoporosis are mostly well protected by anti-osteoporotic treatment in daily clinical practice. However, nephrolithiasis, hypertension, and coronary heart disease can influence the response to prescribed anti-osteoporotic treatment, especially at the total hip level.</p></div>","PeriodicalId":8283,"journal":{"name":"Archives of Osteoporosis","volume":"20 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s11657-025-01604-6.pdf","citationCount":"0","resultStr":"{\"title\":\"Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis\",\"authors\":\"Luis Leal-Vega, María Begoña Coco-Martín, Adrián Martín-Gutiérrez, José Antonio Blázquez-Cabrera, Francisca Arranz-García, Amalia Navarro, María Jesús Moro, José Filgueira, Manuel Sosa-Henríquez, María Ángeles Vázquez, María José Montoya, Manuel Díaz-Curiel, José Manuel Olmos, José Luis Pérez-Castrillón, OSTEOMED Group\",\"doi\":\"10.1007/s11657-025-01604-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>\\n <i>Summary</i>\\n </h3><p>This retrospective cohort study analysed a total of 344 patients from the OSTEOMED registry with matched baseline and follow-up DXA data, finding that comorbidities such as nephrolithiasis, hypertension or coronary heart disease may influence the response to prescribed anti-osteoporotic treatment.</p><h3>Purpose</h3><p>To determine: 1) comorbidities associated with reduced bone mineral density (BMD), T-score and Z-score at the lumbar spine (L1 to L4 vertebrae), femoral neck and total hip; and 2) the role of multimorbidity (≥ 2 comorbidities) in reduced BMD, T-score and Z-score at the lumbar spine, femoral neck and total hip.</p><h3>Methods</h3><p>Retrospective cohort study analyzing patients [319 females (92.73%), 25 males (7.27%), age 62.13 ± 10.46 years] from the OSTEOMED registry with matched baseline and follow-up dual-energy X-ray absorptiometry (DXA) data. Patients' sex, age, body mass index (BMI), comorbidities and treatments were collected from their medical records after they had given written informed consent.</p><h3>Results</h3><p>Considering a least significant change (LSC) of 4.2%, neither comorbidity nor multimorbidity was statistically significantly associated with a reduction in BMD in any of the bone regions studied. However, binary logistic regression analyses adjusted for sex, age, BMI and treatments showed that nephrolithiasis (<i>p</i> = 0.044) and coronary heart disease (<i>p</i> = 0.026) were statistically significantly associated with a reduction in total hip T-score and that hypertension (<i>p</i> = 0.049) and coronary heart disease (<i>p</i> = 0.01) were statistically significantly associated with a reduction in total hip Z-score.</p><h3>Conclusion</h3><p>Despite comorbidity and multimorbidity, patients with osteoporosis are mostly well protected by anti-osteoporotic treatment in daily clinical practice. However, nephrolithiasis, hypertension, and coronary heart disease can influence the response to prescribed anti-osteoporotic treatment, especially at the total hip level.</p></div>\",\"PeriodicalId\":8283,\"journal\":{\"name\":\"Archives of Osteoporosis\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s11657-025-01604-6.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Osteoporosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s11657-025-01604-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Osteoporosis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11657-025-01604-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis
Summary
This retrospective cohort study analysed a total of 344 patients from the OSTEOMED registry with matched baseline and follow-up DXA data, finding that comorbidities such as nephrolithiasis, hypertension or coronary heart disease may influence the response to prescribed anti-osteoporotic treatment.
Purpose
To determine: 1) comorbidities associated with reduced bone mineral density (BMD), T-score and Z-score at the lumbar spine (L1 to L4 vertebrae), femoral neck and total hip; and 2) the role of multimorbidity (≥ 2 comorbidities) in reduced BMD, T-score and Z-score at the lumbar spine, femoral neck and total hip.
Methods
Retrospective cohort study analyzing patients [319 females (92.73%), 25 males (7.27%), age 62.13 ± 10.46 years] from the OSTEOMED registry with matched baseline and follow-up dual-energy X-ray absorptiometry (DXA) data. Patients' sex, age, body mass index (BMI), comorbidities and treatments were collected from their medical records after they had given written informed consent.
Results
Considering a least significant change (LSC) of 4.2%, neither comorbidity nor multimorbidity was statistically significantly associated with a reduction in BMD in any of the bone regions studied. However, binary logistic regression analyses adjusted for sex, age, BMI and treatments showed that nephrolithiasis (p = 0.044) and coronary heart disease (p = 0.026) were statistically significantly associated with a reduction in total hip T-score and that hypertension (p = 0.049) and coronary heart disease (p = 0.01) were statistically significantly associated with a reduction in total hip Z-score.
Conclusion
Despite comorbidity and multimorbidity, patients with osteoporosis are mostly well protected by anti-osteoporotic treatment in daily clinical practice. However, nephrolithiasis, hypertension, and coronary heart disease can influence the response to prescribed anti-osteoporotic treatment, especially at the total hip level.
期刊介绍：
Archives of Osteoporosis is an international multidisciplinary journal which is a joint initiative of the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA. The journal will highlight the specificities of different regions around the world concerning epidemiology, reference values for bone density and bone metabolism, as well as clinical aspects of osteoporosis and other bone diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
